AgingResearch.News
Frontiers in Public Health

Cost-utility analysis of loxenatide versus DPP-4 inhibitors in Chinese patients with type 2 diabetes at high cardiovascular risk

By Longbing Lai, Fengning Chuan, Qiuhong Huang, Show 5 more authorsJiangang Lu
Computational studyInterventions
Paper

The paper

Longbing Lai, Fengning Chuan, Qiuhong Huang, Show 5 more authorsJiangang Lu

Chongqing University

Frontiers in Public Health, 28 Aug 2026

doi.org/10.3389/fpubh.2026.1929706PubMed 42729196

Related